by Madaline Spencer | Jan 7, 2026
The U.S. Food and Drug Administration (FDA) has approved Aqvesme (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia. Alpha- and beta-thalassemia are blood disorders that reduce the body’s production of hemoglobin. Affected people...
by Madaline Spencer | Jan 7, 2026
Ciro Rinaldi, MD, Consultant Hematologist and Professor of Hematology at United Lincolnshire Hospital, discusses treatment with elritercept for patients with myelofibrosis (MF). MF is characterized by the buildup of scar tissue in the bone marrow. The...
by Madaline Spencer | Jan 6, 2026
The U.S. Department of Health and Human Services (HHS) has approved the addition of Duchenne muscular dystrophy (DMD) and metachromatic leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP). DMD and MLD DMD is a rare genetic, neuromuscular condition...
by Madaline Spencer | Jan 6, 2026
Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses updated results from the phase 2 RedirecTT-1 study of telquetamab + teclistamab in patients with multiple myeloma (MM). MM is a form of cancer...
by Madaline Spencer | Jan 5, 2026
The U.S. Food and Drug Administration (FDA) has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). oHCM is a rare genetic heart condition characterized by excessive growth of heart muscle cells....
